Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
#Primary Biliary Cholangitis Therapeutics Market Size Forecast: How Big Could The Market Get By 2030?#_x000D_
The primary biliary cholangitis therapeutics market size has seen swift expansion over recent years. This market is expected to increase from $1.01 billion in 2025 to $1.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.9%. The growth witnessed in the past can be credited to elements such as limited treatment options for PBC, an increasing prevalence of autoimmune liver diseases, enhanced liver disease awareness campaigns, the dependence on ursodeoxycholic acid monotherapy, and the expansion of hospital infrastructure dedicated to liver disease care._x000D_
_x000D_
The primary biliary cholangitis therapeutics market size is set to undergo significant expansion in the coming years. It is forecast to achieve a valuation of $1.85 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.9%. This projected growth is driven by the ongoing development of obeticholic acid and various combination therapies, an increase in investigational drugs and pipeline candidates, the rising adoption of receptor agonists and modulators, increased patient awareness and early diagnosis initiatives, and the expansion of online and retail pharmacy distribution channels. Noteworthy trends for the forecast period include the increasing use of ursodeoxycholic acid and obeticholic acid treatments, the emergence of more combination therapies and pipeline drugs, a greater emphasis on early diagnosis and disease monitoring, the broadening of hospital and retail pharmacy distribution networks, and enhanced awareness regarding autoimmune liver diseases along with patient education._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Primary Biliary Cholangitis Therapeutics Market Expansion Drivers: What’s Shaping Future Growth?#_x000D_
A rising incidence of liver conditions is anticipated to fuel expansion within the primary biliary cholangitis therapeutics market in the coming years. Liver diseases refer to a group of ailments that hinder the liver’s proper operation, frequently resulting in inflammation, fibrosis, or hepatic insufficiency. The growing occurrence of these conditions stems from increased alcohol consumption, as excessive intake damages liver cells, causing inflammation and chronic liver ailments. Primary biliary cholangitis therapeutics aid in managing liver conditions by addressing inflammation in the bile ducts, decelerating the illness’s advancement, and maintaining liver functionality. These treatments enhance patient well-being by alleviating symptoms, improving life quality, and postponing the necessity for liver transplants. For example, in September 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, stated that chronic liver disease and cirrhosis led to 52,222 deaths in the United States in 2023, ranking it as the ninth leading cause of death. Thus, the heightened occurrence of liver diseases is a key factor propelling the expansion of the primary biliary cholangitis therapeutics market._x000D_
_x000D_
#Primary Biliary Cholangitis Therapeutics Market Segment Outlook: Which Categories Are Growing Fastest?#_x000D_
The primary biliary cholangitis therapeutics market covered in this report is segmented – _x000D_
_x000D_
1) By Drug: Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs_x000D_
2) By Mechanism Of Action (MOA): Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action_x000D_
3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies_x000D_
4) By Use: Human, Veterinary_x000D_
_x000D_
Subsegments:_x000D_
1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid_x000D_
2) By Obeticholic Acid: Monotherapy, Combination Therapy, Branded Obeticholic Acid_x000D_
3) By Other Drugs: Fibrates, Budesonide, Immunosuppressants, Investigational Drugs Or Pipeline Candidates_x000D_
_x000D_
#Primary Biliary Cholangitis Therapeutics Market Strategic Trends: What Defines The Next Growth Phase?#_x000D_
Major companies engaged in the primary biliary cholangitis therapeutics market are prioritizing the development of advanced products and the acquisition of approvals, particularly for peroxisome proliferator-activated receptor agonists, with the objective of enhancing bile acid metabolism and decelerating disease progression in patients. Peroxisome proliferator-activated receptor (PPAR) agonists function as drugs that activate PPAR proteins, which are instrumental in regulating genes involved in metabolism, inflammation, and energy balance. For instance, in August 2024, Gilead Sciences Inc., a US-based pharmaceutical company, secured accelerated approval from the U.S. Food and Drug Administration (FDA) for Livdelzi (seladelpar). This approval targets the treatment of primary biliary cholangitis (PBC) in adults who have demonstrated an insufficient response to ursodeoxycholic acid (UDCA) or are unable to tolerate UDCA. Livdelzi (seladelpar) is an oral, selective PPARd agonist that operates by activating the PPARd receptor to regulate genes, consequently reducing liver inflammation, improving bile acid metabolism, and slowing the progression of primary biliary cholangitis (PBC)._x000D_
_x000D_
#Primary Biliary Cholangitis Therapeutics Market Leading Companies And Competitive Benchmarking#_x000D_
Major companies operating in the primary biliary cholangitis therapeutics market are Novartis AG, Gilead Sciences Inc., Ipsen Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics _x000D_
_x000D_
#View The Full Primary Biliary Cholangitis Therapeutics Market Report:#_x000D_
_x000D_
#Primary Biliary Cholangitis Therapeutics Market Regional Distribution: Which Areas Power Market Growth?#_x000D_
North America was the largest region in the primary biliary cholangitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
